United States $755 Billion Pharmaceutical Giant Eli Lilly Buys Cardiovascular Disease Clinic-Stage Company Verve Therapeutics for $1.3 Billion Representing +115% Premium to Closing Price (16/6/25), Founded in 2018 by Sekar Kathiresan, J. Keith Joung & Issi Rozen
18th June | Hong Kong
United States pharmaceutical giant Eli Lilly & Co ($755 billion market value) has announced to buy cardiovascular disease clinic-stage company Verve Therapeutics for $1.3 billion, representing +115% premium to closing price (16/6/25). Verve Therapeutics was founded in 2018 by Sekar Kathiresan, J. Keith Joung & Issi Rozen. Verve Therapeutics – Verve Therapeutics, Inc. (Nasdaq: VERV) is a clinical-stage company developing a new class of genetic medicines for cardiovascular disease with the potential to transform treatment from chronic therapies to single-course gene editing medicines. The company’s lead programs –VERVE-102, VERVE-201, and VERVE-301 – target the three lipoprotein drivers of atherosclerosis: low-density lipoproteins, triglyceride-rich lipoproteins, and lipoprotein(a). VERVE-102 is designed to permanently turn off the PCSK9 gene in the liver and is being developed initially for heterozygous familial hypercholesterolemia and ultimately to treat patients with established atherosclerotic cardiovascular disease (ASCVD) who continue to be impacted by high low-density lipoprotein cholesterol levels. VERVE-201 is designed to permanently turn off the ANGPTL3 gene in the liver and is initially being developed for refractory hypercholesterolemia, where patients still have high low-density lipoprotein cholesterol despite treatment with maximally tolerated standard of care therapies, and homozygous familial hypercholesterolemia. VERVE-301 is designed to permanently turn off the LPA gene to reduce lipoprotein (a) levels. Lipoprotein (a) is a genetically validated, independent risk factor for ASCVD, ischemic stroke, thrombosis, and aortic stenosis. Lilly – Lilly is a medicine company turning science into healing to make life better for people around the world. We’ve been pioneering life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world’s most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer’s disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we’re motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. In 2025 May, Eli Lilly & Company family foundation Lilly Endowment assets increased by +29% from 2023 to $79.9 billion AUM in 2024. Bill Gates & Melinda Gates family foundation (Gates Foundation) has $77.2 billion AUM. Eli Lilly & Company was founded in 1876 by Colonel Eli Lilly. Lilly Endowment was founded in 1937. In 2024 July, Eli Lilly & Co announced to buy biopharmaceutical company Morphic for $3.2 billion, representing 79% premium to closing price on 5th July 2024.
“ United States $755 Billion Pharmaceutical Giant Eli Lilly Buys Cardiovascular Disease Clinic-Stage Company Verve Therapeutics for $1.3 Billion Representing +115% Premium to Closing Price (16/6/25), Founded in 2018 by Sekar Kathiresan, J. Keith Joung & Issi Rozen “
![](https://www.caproasia.com/wp-content/uploads/2025/08/Air-Charter-Service-728x90-1.png")
United States $717 Billion Pharmaceutical Giant Eli Lilly & Company Family Foundation Lilly Endowment Assets Increased by +29% from 2023 to $79.9 Billion AUM in 2024, Bill Gates & Melinda Gates Family Foundation (Gates Foundation) with $77.2 Billion AUM, Eli Lilly & Company Founded in 1876 by Colonel Eli Lilly
17th May 2025 – United States pharmaceutical giant Eli Lilly & Company ($717 billion market value) family foundation Lilly Endowment assets has increased by +29% from 2023 to $79.9 billion AUM in 2024. Bill Gates & Melinda Gates family foundation (Gates Foundation) has $77.2 billion AUM. Eli Lilly & Company was founded in 1876 by Colonel Eli Lilly. Lilly Endowment was founded in 1937. Profile – Lilly was founded in 1876 by Colonel Eli Lilly, a man committed to creating high-quality medicines that met real needs in an era of unreliable elixirs peddled by questionable characters. His charge to the generations of employees who have followed was this: “Take what you find here and make it better and better.” More than 145 years later, we remain committed to his vision through every aspect of our business and the people we serve starting with those who take our medicines, and extending to healthcare professionals, employees and the communities in which we live. Lilly Endowment Inc. was founded in 1937 by J.K. Lilly, Sr. and his sons Eli and J.K. Jr. for the “promotion and support of religious, educational or charitable purposes.” Throughout its history, the Endowment has sought to nurture the human spirit, intellect and character. When once asked what the main purpose of the Endowment should be, Eli Lilly said, “I hope we could help improve the character of the American people.” Our founders viewed character and human development in the context of community and encouraged unselfish concern for the welfare of others. The value they placed on philanthropy, which was in large part motivated by their religious faith, was expressed by Eli Lilly when he said: “Owing everything we are to the past and present generations, each of us must be willing to give unstinted help to others.”
Caproasia Users
- Manage $20 million to $30 billion of assets
- Invest $3 million to $300 million
- Advise institutions, billionaires, UHNWs & HNWs
Caproasia Platforms | 11,000 Investors & Advisors
- Caproasia.com
- Caproasia Access
- Caproasia Events
- The Financial Centre | Find Services
- Membership
- Family Office Circle
- Professional Investor Circle
- Investor Relations Network
Monthly Roundtable & Networking
Family Office Programs
The 2026 Investment Day
- March - Hong Kong
- March - Singapore
- April - Hong Kong
- April - Singapore
- July - Hong Kong
- July - Singapore
- Sept- Hong Kong
- Sept - Singapore
- Oct- Hong Kong
- Nov - Singapore
- Visit: The Investment Day | Register: Click here
Caproasia Summits
- The Institutional Investor Summit
- The Investment / Alternatives Summit
- The Private Wealth Summit
- The Family Office Summit
- The CEO & Entrepreneur Summit
- The Capital Markets Summit
- The ESG / Sustainable Investment Summit
